Graduate School, Anhui University of Chinese Medicine, China.
Graduate School, Anhui University of Chinese Medicine, China; Institute of Neurology, Anhui University of Chinese Medicine, China; Neurology Department, Anhui Hospital of Integrated Traditional Chinese and Western Medicine, China.
Toxicon. 2023 Jan 1;221:106959. doi: 10.1016/j.toxicon.2022.106959. Epub 2022 Nov 4.
Botulinum toxin type A (BoNT-A) has been recommended in various neurological disorders as a useful tool for alleviating dystonia. In Wilson disease (WD) patients with dystonia, BoNT-A injection can be used as a treatment modality when conventional treatment is ineffective for alleviating symptoms. The purpose of this study was to thoroughly evaluate the efficacy of BoNT-A injection in treating WD complicated by lower extremity dystonia. The efficacy of these injections was assessed by clinical scales, surface electromyography (EMG), and gait analysis. A comparative analysis of all gait parameters, EMG parameters, and clinical scales revealed a significant increase in velocity, decrease in integrated EMG (iEMG), and improvement in modified Ashworth scale (MAS), Burke Fahn Marsden (BFM), and activities of daily living (ADL) scores (all P < 0.05). Overall, our findings indicated that BoNT-A injection led to marked relief of symptoms in patients with WD with lower extremity dystonia.
A型肉毒毒素（BoNT-A）已被推荐用于各种神经疾病，作为缓解肌张力障碍的有效工具。对于有肌张力障碍的威尔逊病（WD）患者，当常规治疗不能缓解症状时，肉毒毒素注射可以作为一种治疗方式。本研究的目的是全面评估 BoNT-A 注射治疗 WD 合并下肢肌张力障碍的疗效。通过临床量表、表面肌电图（EMG）和步态分析来评估这些注射的疗效。对所有步态参数、EMG 参数和临床量表进行比较分析，结果显示速度显著增加，整合 EMG（iEMG）减少，改良 Ashworth 量表（MAS）、Burke-Fahn-Marsden（BFM）和日常生活活动（ADL）评分改善（均 P < 0.05）。总的来说，我们的研究结果表明，BoNT-A 注射能显著缓解 WD 合并下肢肌张力障碍患者的症状。
